RPCEC00000348招募中未知
Evaluation of the effect and safety of Biomodulin® T on the immune response in post-chemotherapy cancer patients, from a preventive scenario against the COVID-19 viral disease. Exploratory study (COVID-19) - ONCOBIO-T
ational Center for Bioproducts (BioCen).0 个研究点目标入组 60 人开始时间: 2020年12月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Prevention
入排标准
- 年龄范围
- 65 years 至 one（—）
- 性别
- All
入选标准
- •1. Patients 65 years and over.
- •2. Patients subject to treatment with adjuvant or metastatic CT with finite treatment.
- •3. Tributary patients to chemotherapy schemes according to the Chemotoxicity scale.
- •4. Patients with a life expectancy equal to or greater than 6 months.
- •5. Patients who express, in writing, their consent to participate in the study.
排除标准
- •1. Patients with tumors of the hemolymphopoietic system.
- •2. Patients with criteria for radiotherapy treatment.
- •3. Patients receiving treatment with another research product.
- •4. Patients receiving Immunotherapy treatment (except for colony stimulating factors).
- •5. Patients with known hypersensitivity to any component of the Biomodulin® T formulation.
- •6. Patients with decompensated intercurrent illnesses, including: symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, kidney or liver disease, or other pathology that medically affects the patient's participation in the study.
- •7. Patient with psychiatric or neurotic diseases or memory loss that could limit adherence to the clinical trial.
- •8. Patients with human immunodeficiency virus (HIV).
研究者
相似试验
尚未招募
不适用
Biomodulina T in pediatric septic shock. Exploratory studySystemic Inflammatory Response SyndromeShock, SepticShockPathologic ProcessesPediatricsSeptic shockSepsisRPCEC00000327Centro Nacional de Biopreparados (BioCen)60
招募中
2 期
Evaluation of Biomodulin T® in patients with HIV/AIDS. Phase II/III.HIV InfectionsHuman Immunodeficiency VirusHIVLentiviruses InfectionsRetroviridae InfectionsRNA Viruses InfectionsSexually Transmitted Diseases, ViralImmunologic Deficiency SyndromesImmune System DiseasesEnvironmental IllnessVirus DiseasesSexually Transmitted DiseasesRPCEC00000288ational Center of Bioproducts (BIOCEN)198
招募中
3 期
Biomodulin T Intramuscular for Thymus Hypoplasia in Children. Phase IIIThymus hypoplasiaThymic HypoplasiaThymus Gland /abnormalitiesRPCEC00000247Center National of Bioproducts (BioCen)60
已完成
4 期
Biomodulina T - IM- covid-19 - older adultos - Phase IV clinical trialPrevention of infections, including covid-19Covid-19SARS-CoV2Disease PreventionAgingCoronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusRPCEC00000310Centro Nacional de Biopreparados (BioCen)
招募中
不适用
Biomodulina T- CIMAvax-EGF-Advanced Non-Small Cell Lung Cancer-Adultson-small cell lung cancerCarcinoma, Non-Small-Cell LungCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesRPCEC00000358Center of Molecular Immunology (CIM)